Physician profile
John C Baker
NPI 1659459444
$579.72
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $177 · 2021: $191 · 2022: $91.97 · 2023: $11.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $11.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $11.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $239.98 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.70 | 2020-2021 | |
| Genzyme Corporation | $51.76 | 2019-2021 | |
| Amicus Therapeutics, INC. | $51.02 | 2019-2022 | |
| Shire North American Group INC | $48.06 | 2019 | |
| Travere Therapeutics, INC. | $28.65 | 2019-2023 | Cholbam |
| Biomarin Pharmaceutical INC. | $20.04 | 2021 | |
| Chiesi USA, INC. | $19.26 | 2021 | |
| Pfizer INC. | $14.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.